MA

Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making
Endpoints
Sun, 03/31/19 - 03:53 pm
FDA
Merck KGaA
cladribine
MA
multiple sclerosis